Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry.
暂无分享,去创建一个
Melissa M. Parker | Jennifer Y. Liu | A. Karter | A. Ferrara | J. Selby | H. Moffet | Ameena T. Ahmed | Melissa M. Parker
[1] Melissa M. Parker,et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study: response to Delea et al. , 2004, Diabetes care.
[2] Andrew J Karter,et al. Missed Appointments and Poor Glycemic Control: An Opportunity to Identify High-Risk Diabetic Patients , 2004, Medical care.
[3] W. Ray,et al. Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.
[4] G. Oster,et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. , 2003, Diabetes care.
[5] D. Wysowski,et al. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. , 2003, Diabetes care.
[6] G. Nichols,et al. Slow response to loss of glycemic control in type 2 diabetes mellitus. , 2003, The American journal of managed care.
[7] D. Nathan. Initial Management of Glycemia in Type 2 Diabetes Mellitus , 2002 .
[8] M. Robin DiMatteo,et al. Patient Adherence and Medical Treatment Outcomes: A Meta-Analysis , 2002, Medical care.
[9] Jennifer Y. Liu,et al. Ethnic disparities in diabetic complications in an insured population. , 2002, JAMA.
[10] R. Riegelman,et al. Interaction and intervention modeling: predicting and extrapolating the impact of multiple interventions. , 2002, Annals of epidemiology.
[11] Walter C Willett,et al. Dietary Patterns and Risk for Type 2 Diabetes Mellitus in U.S. Men , 2002, Annals of Internal Medicine.
[12] Rury R Holman,et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). , 2002, Diabetes care.
[13] S. Inzucchi. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. , 2002, JAMA.
[14] A. Karter,et al. Developing a prediction rule from automated clinical databases to identify high-risk patients in a large population with diabetes. , 2001, Diabetes care.
[15] V. Snow,et al. Physician explanations for failing to comply with "best practices". , 2001, Effective clinical practice : ECP.
[16] S. Boccuzzi,et al. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. , 2001, Diabetes care.
[17] B. Anderson,et al. Metabolic control matters: Why is the message lost in the translation? The need for realistic goal-setting in diabetes care. , 2001, Diabetes care.
[18] Jennifer Y. Liu,et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. , 2001, The American journal of medicine.
[19] M. Kalis,et al. Patient‐Reported Adherence to Guidelines of the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure , 2001, Pharmacotherapy.
[20] K. Koh,et al. STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Simvastatin Treats Asians to Target. , 2001, Clinical therapeutics.
[21] T. Valle,et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.
[22] J. Izzo,et al. Treatment of hypertension in a managed care setting. , 2001, The American journal of managed care.
[23] Jan A Staessen,et al. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2) , 2001, Current controlled trials in cardiovascular medicine.
[24] W. Insull,et al. Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks , 2001 .
[25] J. Rosenstock,et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. , 2000, JAMA.
[26] A. Karter,et al. Self-monitoring of blood glucose: language and financial barriers in a managed care population with diabetes. , 2000, Diabetes care.
[27] L. Phillips,et al. Diabetes in urban African-Americans. XVI. Overcoming clinical inertia improves glycemic control in patients with type 2 diabetes. , 1999, Diabetes care.
[28] R. Holman,et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.
[29] B. Stricker,et al. Confounding by indication: an example of variation in the use of epidemiologic terminology. , 1999, American journal of epidemiology.
[30] K. Flegal,et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. , 1999, Diabetes care.
[31] W. Manning,et al. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. , 1997, JAMA.
[32] J. Colwell. Controlling type 2 diabetes: are the benefits worth the costs? , 1997, JAMA.
[33] U. Kabadi,et al. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. , 1996, Archives of internal medicine.
[34] P. Kronsbein,et al. Evaluation of the effectiveness of an ambulatory teaching/treatment programme for non-insulin dependent (type 2) diabetic patients , 1995, Acta Diabetologica.
[35] E. Araki,et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. , 1995, Diabetes research and clinical practice.
[36] R M Poses,et al. Controlling for confounding by indication for treatment. Are administrative data equivalent to clinical data? , 1995, Medical care.
[37] L. Delahanty,et al. The Role of Diet Behaviors in Achieving Improved Glycemic Control in Intensively Treated Patients in the Diabetes Control and Complications Trial , 1993, Diabetes Care.
[38] J. Avorn,et al. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. , 1992, JAMA.
[39] N. Krieger. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. , 1992, American journal of public health.
[40] S. Genuth,et al. Diabetes Control and Complications Trial (DCCT): Results of Feasibility Study. The DCCT Research Group , 1987, Diabetes Care.
[41] M S Kramer,et al. Scientific challenges in the application of randomized trials. , 1984, JAMA.
[42] R. Hiatt,et al. Characteristics of patients referred for treatment of end-stage renal disease in a defined population. , 1982, American journal of public health.
[43] Arshag D Mooradian,et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. , 2002, Diabetes care.
[44] Paula Williams,et al. Stress management improves long-term glycemic control in type 2 diabetes. , 2002, Diabetes care.
[45] J. Wofford. Clinical inertia. , 2002, Annals of internal medicine.
[46] D. Nathan. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. , 2002, The New England journal of medicine.
[47] Anson,et al. DIET , LIFESTYLE , AND THE RISK OF TYPE 2 DIABETES MELLITUS IN WOMEN , 2001 .
[48] W. Insull,et al. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. , 2001, The American journal of cardiology.
[49] 康生 大久保,et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study , 1995 .